Amgen agrees $700m Turkish acquisition

By bne IntelliNews April 26, 2012

Justin Vela in Istanbul -

Amgen, the world's largest biotechnology company, announced on April 25 that it will buy over 95% of Turkey's Mustafa Nevzat Pharmaceuticals (MN Pharma). The $700m deal is the latest in a line of acquisitions by international drugs makers looking to tap into the Turkish market's growing potential.

MN Pharma is a privately owned company specialising in generic injectable drugs. Analysts estimate that generic drugs will account for an ever larger piece of the pie of Turkey's $10bn pharmaceutical market, reports the Financial Times.

Robert A. Bradway, Amgen's president and COO, said: "Together with MN's staff and management team, we plan to grow our business with high quality and innovative medicines in Turkey and the surrounding region." According to MN Pharma, the company's exports are growing rapidly.

In a joint statement, the two companies said that the transaction will boost Amgen's presence in a region that has "large, fast-growing, priority markets," reports Bloomberg.

In the past five years, MN Pharma's revenues have increased by more than 10% annually - it reported revenue of $200m in 2011 - while the wider Turkish pharmaceutical market has put in a generally sluggish performance.

Despite that, the US company is looking to tap the potential of Turkey and its surrounding markets, with economic growth set to power demand for pharmaceuticals. One in every five drugs sold in 2020 will be purchased in China, Russia, Brazil, India, Mexico, Indonesia and Turkey, according to a recent report by PricewaterhouseCoopers.

Amgen joins a growing list of international pharmaceuticals looking to leverage that forthcoming growth. In September, Italy's Recordati bought Dr F Frik Ilac and Poland's Polpharma acquired Cenovapharma in May, just after European pharmaceutical company Nycomed entered into distribution agreements with several local players.

Reform is also part of the story. The government has carried out large-scale health reforms, which have increased many people's access to medical services. Around 98% of the population is now covered by social security.

Meanwhile, Turkey's healthcare spending is spiking. The sector has consistently consumed around 6% of GDP in recent years, whilst the country has seen rapid economic growth over the same period. With a huge social security deficit to deal with, the government is pushing to increase the use of generics as a cost saving measure, with just over half of the market taken by generic drugs.

Related Articles

Turkey approaches day of reckoning on economic reform

Kivanc Dundar in Istanbul -   The unexpected success of President Recep Tayyip Erdogan’s Justice and Development Party (AKP) in this month’s general election should bring much-desired political ... more

Macedonia kept on hold as Balkans edges towards EU goal

Clare Nuttall in Bucharest -   Macedonia’s EU accession progress remains stalled amid the country’s worst political crisis in 14 years, while most countries in the Southeast Europe region have ... more

Turkey and America seen on course for confrontation in Syria war

John Davison of Exaro - Military action by Turkey against Kurdish rebel forces in Syria raises the prospect of a direct clash with the ... more

Register here to continue reading this article and 2 more for free or purchase 12 months full website access including the bne Magazine for just $119/year.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

Thank you. Please complete your registration by confirming your email address.
A confirmation email has been sent to the email address you provided.

To continue viewing our content you need to complete the registration process.

Please look for an email that was sent to with the subject line "Confirmation bne IntelliNews access". This email will have instructions on how to complete registration process. Please check in your "Junk" folder in case this communication was misdirected in your email system.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

If you have any questions please contact us at sales@intellinews.com

Subscribe to bne IntelliNews website and magazine

Subscribe to bne IntelliNews website and monthly magazine, the leading source of business, economic and financial news and commentary in emerging markets.

Your subscription includes:
  • Full access to the bne content daily news and features on the website
  • Newsletters direct to your mailbox
  • Print and digital subscription to the monthly bne magazine
  • Digital subscription to the weekly bne newspaper

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

bne IntelliNews
$119 per year

All prices are in US dollars net of applicable taxes.

If you have any questions please contact us at sales@intellinews.com

Register for free to read bne IntelliNews Magazine. You'll receive a free digital subscription.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

Thank you. Please complete your registration by confirming your email address.
A confirmation email has been sent to the email address you provided.

IntelliNews Pro offers daily news updates delivered to your inbox and in-depth data reports.
Get the emerging markets newswire that financial professionals trust.

"No day starts for my team without IntelliNews Pro" — UBS

Thank-you for requesting an IntelliNews Pro trial. Our team will be in contact with you shortly.

Dismiss